1. Home
  2. VLN vs DRUG Comparison

VLN vs DRUG Comparison

Compare VLN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLN
  • DRUG
  • Stock Information
  • Founded
  • VLN 2006
  • DRUG 2019
  • Country
  • VLN Israel
  • DRUG United States
  • Employees
  • VLN N/A
  • DRUG N/A
  • Industry
  • VLN Semiconductors
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • VLN Technology
  • DRUG Health Care
  • Exchange
  • VLN Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • VLN 236.8M
  • DRUG 233.2M
  • IPO Year
  • VLN N/A
  • DRUG N/A
  • Fundamental
  • Price
  • VLN $2.22
  • DRUG $27.31
  • Analyst Decision
  • VLN Strong Buy
  • DRUG Strong Buy
  • Analyst Count
  • VLN 1
  • DRUG 6
  • Target Price
  • VLN $4.00
  • DRUG $83.25
  • AVG Volume (30 Days)
  • VLN 267.0K
  • DRUG 19.6K
  • Earning Date
  • VLN 08-06-2025
  • DRUG 08-13-2025
  • Dividend Yield
  • VLN N/A
  • DRUG N/A
  • EPS Growth
  • VLN N/A
  • DRUG N/A
  • EPS
  • VLN N/A
  • DRUG N/A
  • Revenue
  • VLN $63,128,000.00
  • DRUG N/A
  • Revenue This Year
  • VLN $25.99
  • DRUG N/A
  • Revenue Next Year
  • VLN $17.25
  • DRUG N/A
  • P/E Ratio
  • VLN N/A
  • DRUG N/A
  • Revenue Growth
  • VLN N/A
  • DRUG N/A
  • 52 Week Low
  • VLN $1.67
  • DRUG $0.93
  • 52 Week High
  • VLN $3.50
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • VLN 52.11
  • DRUG 41.95
  • Support Level
  • VLN $1.99
  • DRUG $27.69
  • Resistance Level
  • VLN $2.28
  • DRUG $28.74
  • Average True Range (ATR)
  • VLN 0.09
  • DRUG 1.29
  • MACD
  • VLN 0.01
  • DRUG 0.14
  • Stochastic Oscillator
  • VLN 93.10
  • DRUG 39.29

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: